Do high day 1 dsDNA levels associate with myocardial infarct size, adverse left ventricular remodeling, and clinical outcome in patients with STEMI?
High day 1 dsDNA levels following STEMI may serve as a biomarker for larger infarct size, adverse left ventricular remodeling, and worse clinical outcomes.
High day 1 dsDNA levels after STEMI were associated with myocardial infarct size, adverse left ventricular remodeling, and clinical outcome. Although the origin of dsDNA could be discussed, these observations indicate a potential role for dsDNA in acute myocardial ischemia. This trial is registered with S-08421d, 2008/10614 (Regional Committee for Medical Research Ethics in South-East Norway (2008)).
Helseth et al. (Mon,) studied this question.